NCT-58 structure
|
Common Name | NCT-58 | ||
---|---|---|---|---|
CAS Number | 2411429-33-7 | Molecular Weight | 466.57 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C27H34N2O5 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of NCT-58NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells[1]. |
Name | NCT-58 |
---|
Description | NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells[1]. |
---|---|
Related Catalog | |
Target |
HSP90 Apoptosis |
In Vitro | NCT-58 treatment (0.1-20 μM; 72 hours) dose-dependently reduces cell viability in HER2-positive BT474 and SKBR3 cells[1]. NCT-58 treatment (0.1-10 μM; 72 hours) increases the number of early and late apoptotic cells in HER2-positive BT474 and SKBR3 cells[1]. NCT-58 treatment (2-10 μM; 72 hours) effectively reduced the levels of truncated p95HER2 and its phosphorylated form, as well as downregulation of Akt and phospho-Akt (Ser473) protein contents in JIMT-1 and MDA-MB-453 cells[1]. Cell Viability Assay[1] Cell Line: BT474 and SKBR3 cells Concentration: 0, 0.1, 0.5, 1, 5, 10, 15, 20 μM Incubation Time: 72 hours Result: Significantly reduced cell growth. Apoptosis Analysis[1] Cell Line: BT474 and SKBR3 cells Concentration: 0, 2, 10 μM Incubation Time: 72 hours Result: Increased the number of early and late apoptotic cells. Western Blot Analysis[1] Cell Line: Trastuzumab-resistant JIMT-1 and MDA-MB-453 cells Concentration: 0, 2, 10 μM Incubation Time: 72 hours Result: Effectively reduced the levels of truncated p95HER2 and its phosphorylated form, as well as downregulation of Akt and phospho-Akt (Ser473) protein contents in JIMT-1 and MDA-MB-453 cells. |
In Vivo | NCT-58 (30 mg/kg; i.p.; every other day for 47 days) suppresses Trastuzumab-resistant tumor growth[1]. NCT-58 (30 mg/kg; i.p.; every other day for 47 days) causes a significant impediment of tumor growth and a marked decrease in tumor weight[1]. Animal Model: Trastuzumab-resistant xenograft model (female nude mice; 6 weeks; BALB/c)[1] Dosage: 30 mg/kg Administration: i.p.; every other day for 47 days Result: Significantly reduced tumor growth. |
References |
Molecular Formula | C27H34N2O5 |
---|---|
Molecular Weight | 466.57 |
Storage condition | -20°C |